Preeclampsia Ratio (sFlt-1/PlGF) (NCT03289611) | Clinical Trial Compass
CompletedNot Applicable
Preeclampsia Ratio (sFlt-1/PlGF)
France84 participantsStarted 2018-04-26
Plain-language summary
The aim of the PRECOG study is to determine in a prospective interventional randomized study whether the implementation of a predictive test based on the sFLT-1/PlGF ratio improves perinatal care and reduces costs, in patients with suspected preeclampsia before 35 weeks of gestation.
Who can participate
Age range18 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Patient hospitalized for suspected preeclampsia between 24WG+ 0 days and 35WG + 6 days,
Patiente with at least one of the following criteria:
* Arterial hypertension defined by systolic BP ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg
* Proteinuria greater than 0.3g / 24h or 0.3g / l or ≥ 3+
* Proteinuria / creatinine ratio ≥ 30 mg / mmol
* Pain in the epigastric bar
* Generalized edema
* Hepatic cytolysis\> 1.5N
* Thrombocytopenia \<150000 / mm3 Informed consent signed by both parties Non-opposition was accepted by parental authority Age ≥ 18 years
Exclusion Criteria:
Diagnosis of preeclampsia (arterial pressure\> 140/90 and proteinuria\> 0.3g / 24h or urine test\> 3+) or complete HELLP syndrome (Platelets \<100000 / mm3 and SGOT\> 2N and LDH and collapsed Haptoglobin)
IUGR with absent or reverse diastolic umbilical flow
Fetal heart rate abnormalities
Gestational age \<24 WG and\> 35 WG
Multiple pregnancy
Patient without health insurance
Non-consent of patient
Minor patient
Congenital malformation
What they're measuring
1
number of patients hospitalised for more than 24 hours